Development of a Novel Anti-CD44 Variant 4 Monoclonal Antibody C₄₄Mab-108 for Immunohistochemistry.

ABSTRACT: CD44 has been known as a marker of tumor-initiating cells, and plays pro-tumorigenic functions in many cancers. The splicing variants play critical roles in the malignant progression of cancers by promoting stemness, cancer cell invasion or metastasis, and resistance to chemo- and radiotherapy. To understand each CD44 variant (CD44v) function is essential to know the property of cancers and the establishment of the therapy. However, the function of the variant 4-encoded region has not been elucidated. Therefore, specific monoclonal antibodies (mAbs) against variant 4 are indispensable for basic research, tumor diagnosis, and therapy. In this study, we established anti-CD44 variant 4 (CD44v4) mAbs by immunizing mice with a peptide containing the variant 4-encoded region. We next performed f

SUBMITTER: Suzuki H 

PROVIDER: S-EPMC10047040 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature